Currently, RAPT Therapeutics Inc [RAPT] is trading at $10.61, up 21.67%. An important factor to consider is whether the stock is rising or falling in short-term value. The RAPT shares have gain 32.13% over the last week, with a monthly amount glided 21.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright upgraded its rating to Buy on December 26, 2024, and kept the price target unchanged to $10. On November 13, 2024, downgrade downgraded it’s rating to Hold and revised its price target to $2 on the stock. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $2 on November 11, 2024. JP Morgan downgraded its rating to a Underweight. Wolfe Research downgraded its rating to Peer Perform for this stock on May 14, 2024. In a note dated May 10, 2024, Guggenheim downgraded an Neutral rating on this stock.
This stock has fluctuated between a low of $5.67 and a high of $30.60 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $30.71 within the next 12 months. RAPT Therapeutics Inc [NASDAQ: RAPT] shares were valued at $10.61 at the most recent close of the market. An investor can expect a potential return of 189.44% based on the average RAPT price forecast.
Analyzing the RAPT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.62, Equity is -0.81 and Total Capital is -0.69. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.12 points at the first support level, and at 7.63 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.02, and for the 2nd resistance point, it is at 13.43.
Ratios To Look Out For
To put it in perspective, the Current Ratio for RAPT Therapeutics Inc [NASDAQ:RAPT] is 21.11. On the other hand, the Quick Ratio is 21.11, and the Cash Ratio is 6.94.
